Atavistik Bio
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 Cambridgepark Dr Ste 3, Cambridge, M...Website
www.atavistikbio.comRevenue
$9.7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Atavistik Bio
Atavistik Bio is a clinical stage biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery.Explore more
Atavistik Bio Org Chart
SP
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Atavistik Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Atavistik Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if Atavistik Bio had a recent Job posting/layoffs
Product Launch: Get notified when Atavistik Bio launches new products
Congratulate Masked Content for being promoted to Masked Content at Atavistik Bio
Earning: See what the market has to say on Atavistik Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Atavistik Bio is spiking on competitors!
Funding: Get notified immidiatlly once Atavistik Bio has new funding data
Atavistik Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Atavistik Bio
Find 2 more new buyers
Compare Similar Companies to Atavistik Bio
Compare insights from companies similar to Atavistik Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Atavistik Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Atavistik Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Atavistik Bio.
Atavistik Bio financials insights
Gather financial insights about Atavistik Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$60M
Series A
$60M
2022
Series A
$60M
2023
Other Financing Round
$40M
2025
Series B
$120M
Atavistik Bio Tech Stack
A closer look at the technologies used by Atavistik Bio
See more technologies
Most Recent Scoops
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Funding
Funding
Atavistik Bio News & Media
New funding, new jobs: 4 biotechs hiring after series B raises - BioSpace
Biotechs that announced series B financing this year and are looking for employees as they grow include one that received over $100 million and another that has a partnership with a Big Pharma company.Atavistik Bio Appoints Habib Dable to its Board of Directors
Mr. Dable brings deep expertise in clinical development, commercialization, and corporate strategy to support Atavistik Bio’s next phase of growth Mr. Dable brings deep expertise in clinical development, commercialization, and corporate strategy to support Atavistik Bio’s next phase of growthAtavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio announces U.S. FDA clearance of investigational new drug application and Fast Track Designation for ATV-601 for the treatment of HHT.Next-generation allosteric modulators: A glance at the biotech pipeline in 2026
We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through the clinic.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Atavistik Bio
Sign Up For FreeTo access detailed company insights
Atavistik Bio is a clinical stage biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and... Read More
